Treatment Duration of Adjuvant Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Patients at High Risk of Recurrence after Resection: A Prospective, Multicentric Cohort Study

<p>Introduction: Adjuvant immune checkpoint inhibitors (ICIs) may improve recurrence-free survival (RFS) in patients with hepatocellular carcinoma (HCC). This study evaluated the effects of adjuvant ICI treatment duration on RFS and overall survival (OS) among patients with HCC at high ri...

Full description

Bibliographic Details

Main Authors:	Jia-Yong Su, Shao-Ping Liu, Xiao-Ling Xu, Jun-Jie Ou, Po-Hua Ye, Bin-Tong Zhao, Jia-Song Chen, Qiu-Mei Luo, Jin-Rong Liu, Fei-Min Tang, Jian-Rong Li, Da-Long Yang, Zhu-Jian Deng, Li-Xin Pan, Yao-Jie Li, Le Li, Zhen-Ming Qin, Xiu-Mei Liang, Yi-Li Ma, Liang Ma, Jian-Hong Zhong
Format:	Artigo
Language:	Inglês
Published:	Karger Publishers 2025-01-01
Series:	Liver Cancer
Online Access:	https://karger.com/article/doi/10.1159/000542954
Tags:	Add Tag No Tags, Be the first to tag this record!